Data Sheet (Cat.No.T13845)

TargetMol

PROTAC PARP1 degrader

Chemical Properties



CAS No. : 2369022-68-2

Formula: C58H63Cl2N11O10

Molecular Weight: 1145.1

Storage: Keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	PROTAC PARP1 degrader is a targeted protein degrader of PARP1 developed using PROTAC technology, and at 10 μM for 24 hours inhibits the proliferation of the MDA-MB-231 breast cancer cell line with an IC50 of 6.12 μM, providing a powerful research tool for studying DNA damage response, PARP1 biology, and degradation-based cancer therapeutics.
Targets(IC50)	PARP,PROTACs
In vitro	In MDA-MB-231 breast cancer cells, PROTAC PARP1 degrader exhibits antiproliferative activity with an IC_{50} of 8.45 μM after 24 hours of incubation [1][2].

Solubility Information

Solubility	DMSO: 80 mg/mL (69.86 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.8733 mL	4.3664 mL	8.7329 mL
5 mM	0.1747 mL	0.8733 mL	1.7466 mL
10 mM	0.0873 mL	0.4366 mL	0.8733 mL
50 mM	0.0175 mL	0.0873 mL	0.1747 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Zhao Q, et al. Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule. Chem Commun (Camb). 2019 Jan 2;55(3):369-372.
Zhang J, et al. Multi-therapies Based on PARP Inhibition: Potential Therapeutic Approaches for Cancer Treatment. J Med Chem. 2022 Dec 22;65(24):16099-16127.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481